期刊文献+

局部肌层浸润性膀胱癌预后影响因素分析 被引量:9

Prognostic Factors of Patients with Local Muscle-invasive Bladder Cancer
暂未订购
导出
摘要 目的:探讨影响局部肌层浸润性膀胱癌患者长期生存的预后因素方法:回顾性分析2002年1月至2011年6月新疆医科大学第一附属医院肿瘤中心收治的133例局部浸润性膀胱癌患者临床资料,选择年龄、合并症、肾积水、肿瘤大小、病灶数目、T分期、淋巴结转移、病理类型、肿瘤分级、治疗方式等10个对预后可能产生影响的因素,采用Kaplan-Meier法和Log-rank检验,对有意义的单因素进行Cox多因素分析。结果:随访4~114个月,全组患者1、3、5年生存率分别为77%、64%、52%。单因素分析显示T分期、淋巴结及肾积水对预后的影响有统计学意义(P<0.05)。Cox多因素分析显示影响局部肌层浸润性膀胱癌患者预后的因素分别为:T分期(RR=2.001,P=0.001)、淋巴结(RR=2.250,P=0.045)、肾积水(RR=1.954,P=0.047)。结论:肿瘤T分期。 Objective: This study aims to investigate the prognostic factors affecting the survival of patients with local muscle-invasive bladder cancer. Methods: The clinical and follow-up data of 133 patients with local muscle-invasive bladder cancer were retrospectively analyzed. Fourteen possible prognostic factors included gender, age, nationality, smoking habits, alcohol drinking habits, coexisting disease, hydronephrosis, tumor size, multifocality, T stage, lymph node staging, pathological type, histological grade, treatments via the Kaplan-Meier method, or the Log-rank test. Multivariate analysis was performed using the Cox proportional hazard model. Results: The follow-up period ranged from 4 months to 114 months. The 1-, 3-, and 5-year survival rates were 77%, 64%, and 52%, respectively. Univariate analysis showed that the T stage, lymph node staging, and hydronephrosis were prognosis factors ( P 〈 0.05 ). Multivariate analysis by the Cox proportional hazard model showed T stage ( RR = 2.001, P = 0.001 ), lymph node staging ( RR =2.250, P= 0.045 ), and hydronephrosis ( RR=1.954, P= 0.047 ) as the prognostic factors ( P〈 0.05 ). Conclusion: Hydronephrosis, T stage, and lymph node staging were prognostic factors of local muscle-invasive bladder cancer.
出处 《中国肿瘤临床》 CAS CSCD 北大核心 2012年第9期593-596,共4页 Chinese Journal of Clinical Oncology
基金 乌鲁木齐市科学技术项目(编号:H111313001)资助~~
关键词 浸润性膀胱癌 COX比例风险模型 预后因素 Bladder neoplasms Cox proportional hazard model Prognostic factors
  • 相关文献

参考文献4

二级参考文献44

  • 1李黎明,章鸣放.图象分析法DNA及形态学参数与膀胱癌恶性度及预后的关系[J].中华泌尿外科杂志,1993,14(5):379-382. 被引量:1
  • 2John PS, Donald G, et al. Partial and radical cystectomy//Jerome P, Anthony V, eds. Urologic Oncology. Elsevier: Saunders,2005 : 368-369.
  • 3Dunst J, Rodel C, Zietman A, et al. Bladder preservation in muscle-invasive bladder cancer by conservative surgery and radiochemotherapy. Semin Surg Oncol,2001,21:24-32.
  • 4Kaufman'DS, Winter KA,Shipley WU,et al. The initial results in muscle - invading bladder cancer of RTOG 95-06 : phase Ⅰ/Ⅱ trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response. Oncologist, 2000,5:471-476.
  • 5Danesi DT, Arcangeli G, Cruciani E, et al. Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy : long term results. Cancer,2004,101:2540-2548.
  • 6George L,Bladou F,Bardou VJ,et al. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy. Urology ,2004,64:488-493.
  • 7Parsons JT, Million PR. Bladder//Perez CA. Principles and practice of radiation oncology. 2nd ed. Philadelphia: JB Lippincott, 1992 : 1036.
  • 8Shipley WU, Winter KA, Kaufman DS, et al. Phase Ⅲ trial of newadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy : initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol, 1998.16:3576-3583.
  • 9Shipley WU, Kaufman DS, Tester WJ, et al. Overview of bladder cancer trials in the Radiation Therapy Oncology Group. Cancer, 2003,97(8 Supp 1) :2115-2119.
  • 10Rodel C, Grabenbauer GG, Kuhn R, et al. Combined modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin 0ncol,2002,20:3061-3071.

共引文献20

同被引文献97

  • 1Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010 EJ-. CA Cancer J Clin,2010,60(5) : 277-300.
  • 2Bassi P,De Marco V,De Lisa A,et al. Non-invasive di- agnostic tests for bladder cancer., a review of the litera- ture[J]. Urol Int. 2005,75(3) .. 193-200.
  • 3Celis J E, Gromova I, Moreira J M, et al. Impact of pro teornics on bladder cancer research [J]. Pharmacog enomics. 2004,5 (4) .. 381-394.
  • 4Konety B R. Molecular markers in bladder cancer: A c/'itical appraisal[J]. Urol Oncol. 2006,24 (4) : 326-337.
  • 5Feil G,Stenzl A. Tumor marker tests in bladder cancer [J]. Actas Urol Esp. 2006,30(1)38-45.
  • 6Svatek R S,Sagalowsky A L,Lotan Y. Economic im- pact of screening for bladder cancer using bladder tumor markers: A decision analysis[J]. Urol Oncol. 2006,24 (4) : 338-343.
  • 7Fujii Y, Kawakami S, Koga F, et al. Long-term outcome of bladder papillary urothelial neoplasms of low malignant potential[J]. BJU Int, 2003,92(6) 559-562.
  • 8Osterlinck W. Guideliness on diagnosis and treatment of superficial bladder eancer[J]. Minerva Urol Nefrol. 2004,56(1) :65-72.
  • 9Roberts J T. Chemotherapy for metastatic bladder cancer[J]. Clin Oncol. 2005,17(7) .. 514-523.
  • 10Sternberg CN,Calabro F. Adjuvant chemotherapy for bladder cancer E J ]. Expert Rev Anticancer Ther. 2005,5(6) :987-998.

引证文献9

二级引证文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部